Next-Gen PARP Inhibitor Effective in Breast Cancer

New data from the PETRA clinical trial suggest that the PARP1 inhibitor saruparib induces durable responses in patients with HER-negative breast cancer. Researchers found that the maximum tolerated dose of 90 mg per day produced an overall response rate of 46.7% and median duration of response of 5.6 months. The values for a dose of 60 mg were 48.4% and 7.3 months, leading the researchers to choose this as the optimal dose.